TrialNeuro-oncology2020

A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study.

Nicole J Ullrich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.